Merck revises Arcoxia NDA
Merck is withdrawing the NDA for its COX-2 inhibitor Arcoxia (etoricoxib) and refiling with additional ankylosing spondylitis efficacy data. "Merck believes the new data, along with the data previously submitted, will provide a fuller picture of the product's safety and efficacy and will position it more favorably for approval in the U.S." Additional studies are not needed; Merck has the ankylosing spondylitis data on hand. Merck filed the Vioxx follow-on Oct. 11. Arcoxia may be reviewed by FDA's Arthritis Advisory Committee in mid-May (1"The Pink Sheet" March 4, In Brief)...
You may also be interested in...
The liver safety profile of Novartis' Prexige appears to be one factor behind FDA's request for additional studies on the COX-2 inhibitor prior to approval in osteoarthritis and acute pain
Sponsors seeking a disease-modifying claim for an ankylosing spondylitis indication should assess the radiographic progression of the disease, FDA's Arthritis Advisory Committee agreed during its June 24 review of Amgen/Wyeth's Enbrel
Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events